Novartis (NYSE:NVS) issued its quarterly earnings results on Tuesday. The company reported $1.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.52 by $0.14, MarketWatch Earnings reports. Novartis had a net margin of 16.31% and a return on equity of 24.15%. The company had revenue of $12.96 billion during the quarter, compared to analysts’ expectations of $12.41 billion. During the same quarter last year, the company posted $1.36 EPS. The firm’s revenue was up 14.2% compared to the same quarter last year.
NYSE NVS opened at $90.48 on Thursday. The company has a current ratio of 0.74, a quick ratio of 0.50 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $207.08 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 2.15 and a beta of 0.55. Novartis has a one year low of $77.04 and a one year high of $98.52. The company has a fifty day simple moving average of $90.96.
A hedge fund recently raised its stake in Novartis stock. OLD Mission Capital LLC raised its holdings in Novartis AG (NYSE:NVS) by 85.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 367,985 shares of the company’s stock after purchasing an additional 169,219 shares during the quarter. Novartis comprises approximately 2.0% of OLD Mission Capital LLC’s portfolio, making the stock its 5th largest holding. OLD Mission Capital LLC’s holdings in Novartis were worth $32,000,000 as of its most recent SEC filing. 9.50% of the stock is owned by institutional investors and hedge funds.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.
See Also: 52 Week Highs
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.